While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
The new Omicron SARS-CoV2 variant first identified in South Africa but now appearing in Asia and Europe is causing alarm worldwide as its multiple mutations could make it more transmissible than the Delta variant, and potentially able to evade existing vaccines.
News of the variant, also known as B.1.1.529, sent global share prices plummeting on 26 November, with countries imposing new...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
